John Maher

Dr John Maher is the scientific founder and chief scientific officer of Leucid Bio. He is also a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. In addition, he is a consultant immunologist at Eastbourne Hospital.